secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001104659-23-057986
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bayer and Bicycle Therapeutics enter $1.7B collaboration for radiopharmaceuticals; $45M upfront
--------------------------------------------------------------------------------

- Bicycle receives $45M upfront; total potential milestones up to $1.7B across up to three oncology targets.
- Bayer fully funds all preclinical, clinical, manufacturing, and commercialization activities.
- Bicycle eligible for mid-single to double-digit tiered royalties on commercialized products.
- Closing subject to clearance under U.K. National Security and Investment Act 2021.
- Collaboration uses Bicycle's bicyclic peptide technology to develop radioconjugates for undisclosed targets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465923057986/0001104659-23-057986-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465923057986/tm2314992d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-057986

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer